Condition

Recurrent Multiple Myeloma clinical trials and research

• 11Clinical trials
• 1Country

Newest Recurrent Multiple Myeloma clinical trials

All recruiting trials (11)

• Infliximab to Help Prevent CRS During Teclistamab or Talquetamab Therapy in Relapsed/Refractory Myeloma

  This phase 2 trial tests whether infliximab can prevent cytokine release syndrome in patients with relapsed or refractory multiple myeloma who are being treated with teclistamab or talquetamab.

  Recruiting Phase 2 Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT07657312

• Cognitive training to help brain function in people getting CAR-T therapy for relapsed or refractory blood cancers

  A brain-training program given before and after CAR-T therapy is tested to see if it helps cognitive and neurological outcomes for adults with relapsed or refractory multiple myeloma or B-cell non-Hodgkin lymphoma.

  Recruiting Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT07609030

• Teclistamab plus pomalidomide vs standard therapy for relapsed multiple myeloma

  This study tests whether the combination of teclistamab and pomalidomide can work better than the usual regimen (carfilzomib, pomalidomide, and dexamethasone) for adults whose multiple myeloma has returned after some improvement.

  Recruiting Phase 1/2 National Cancer Institute (NCI) · Duarte, California · NCT07463807

• Response-based lowering of linvoseltamab doses for relapsed or refractory multiple myeloma

  This trial tests whether lowering linvoseltamab doses for people with relapsed or refractory multiple myeloma can control the cancer while reducing side effects.

  Recruiting Phase 1/2 Fred Hutchinson Cancer Center · Seattle, Washington · NCT07181941

• Daratumumab‑hyaluronidase plus teclistamab vs standard daratumumab combinations for high‑risk relapsed or refractory multiple myeloma

  This phase 2 trial tests whether combining daratumumab with teclistamab helps people with high‑risk myeloma that has not responded to treatment or has come back, compared to usual daratumumab‑based therapies.

  Recruiting at 32 sites Phase 2 National Cancer Institute (NCI) · Coeur d'Alene, Idaho and 31 other locations · NCT06948084

• Dasatinib and quercetin plus preparation chemotherapy before CAR-T for relapsed or refractory multiple myeloma

  This phase II test will see whether adding dasatinib and quercetin to preparation chemotherapy and CAR-T cell therapy helps people with relapsed or refractory multiple myeloma.

  Recruiting Phase 2 Mayo Clinic · Rochester, Minnesota · NCT06940297

• Combination treatment for relapsed multiple myeloma using iberdomide, daratumumab, elotuzumab, and dexamethasone

  This study is testing a new combination of four medications to see if it can help people with relapsed multiple myeloma feel better and live longer.

  Recruiting Phase 1/2 Mayo Clinic · Rochester, Minnesota · NCT06785415

• Treatment for relapsed or refractory multiple myeloma with extramedullary disease

  This study is testing a new combination of medications to see if it can help people with relapsed or hard-to-treat multiple myeloma that has spread outside the bone marrow.

  Recruiting Phase 2 Roswell Park Cancer Institute · Buffalo, New York · NCT06627751

• Combining SX-682 with standard treatments for relapsed or refractory multiple myeloma

  This study is testing if adding a new drug called SX-682 to standard treatments can help people with relapsed or refractory multiple myeloma feel better and fight their cancer more effectively.

  Recruiting Phase 1 Roswell Park Cancer Institute · Buffalo, New York · NCT06622005

• Testing a new combination treatment for relapsed or refractory multiple myeloma

  This study is testing a new combination of two treatments, iberdomide and teclistamab, to see if they can help people with relapsed or refractory multiple myeloma feel better and fight their cancer more effectively.

  Recruiting at 16 sites Phase 1 National Cancer Institute (NCI) · Phoenix, Arizona and 16 other locations · NCT06465316

• Testing different doses and schedules of belantamab mafodotin for treating tough cases of multiple myeloma

  This study is testing different doses and schedules of a new cancer treatment called belantamab mafodotin to see if it helps people with tough cases of multiple myeloma feel better and live longer.

  Recruiting Phase 2 Mayo Clinic · Jacksonville, Florida · NCT05847569

Related topics

Quick answers

How many Recurrent Multiple Myeloma clinical trials are recruiting right now?

11, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

All of them have sites in United States. Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 5, Phase 1/2: 3, Phase 1: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →